Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., Rosovsky, R., Lilenbaum, R., Bastos, B. R., Huang, C., Johnson, M. L., Hasketh, P. J., Subramaniam, D. S., Chai, F., Kazakin, J., Schwartz, B. E., Schiller, J. H., Brahmer, J. R. ELSEVIER SCIENCE INC. 2014: S36

View details for Web of Science ID 000346413500076